Research programme: anti-cancer immune-based therapies - Evotec SE/Janssen Biotech
Latest Information Update: 09 Feb 2023
At a glance
- Originator Evotec SE
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer